Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2024-03-19 Annual Report
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2023.12)
Annual Report Classification · 1% confidence The document is a 'Correction of Business Report' (사업보고서 정정) for Access Bio, Inc. It contains detailed financial tables, including revenue by product, production capacity, and risk management disclosures (credit, liquidity, market risk). This level of detailed financial data and management analysis constitutes a comprehensive financial report for a specific period, fitting the definition of an Interim/Quarterly Report (IR) or Annual Report (10-K). Given the context of a 'Business Report' (사업보고서) in the Korean regulatory framework, which serves as the primary annual financial disclosure, it is classified as an Annual Report (10-K). FY 2023
2024-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Access Bio. It contains the auditor's opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit/loss) for both consolidated and separate financial statements, and details regarding the audit process. While it provides financial data, it is a specific regulatory filing required by the KRX (Korea Exchange) to announce the completion and submission of the audit report, rather than the full Annual Report (10-K) itself. Therefore, it is classified as an Audit Report/Information document. FY 2023
2024-03-18 Korean
사업보고서 (2023.12)
Annual Report Classification · 1% confidence The document is a '사업보고서' (Business Report) for the 22nd fiscal year (2023) of Access Bio, Inc. It contains comprehensive financial statements, management discussion and analysis (MDA), audit information, and detailed operational data. In the context of Korean corporate filings (DART system), this is the equivalent of an Annual Report (10-K). FY 2023
2024-03-18 Korean
전환가액의조정 (제5회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Access Bio regarding the adjustment of the conversion price for its 5th series convertible bonds (CB). This type of filing, which details changes to capital structure instruments like convertible debt, falls under the 'Capital/Financing Update' category as it directly relates to financing activities and the terms of outstanding debt securities.
2024-03-11 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Access Bio, Inc. It contains the agenda for the upcoming Annual General Meeting (AGM), including voting items, financial statements, and proxy solicitation information for shareholders to exercise their voting rights. While it contains financial data, it is primarily a proxy statement/notice for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Access Bio) announcing a significant change (over 30%) in revenue and profit structure compared to the previous fiscal year. This is a standard 'Earnings Release' or 'Preliminary Financial Results' announcement required by the Korea Exchange (KRX) when financial performance deviates significantly from prior periods. It provides key financial highlights (revenue, operating profit, net income) and the primary reason for the change (COVID-19 endemic transition). It is not a full annual report, but rather an initial disclosure of financial results. FY 2023
2024-02-28 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.